The clinical study of TKI combined with chemotherapy as first-line therapy for non small cell lung cancer

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-13003772

Enrollment

Unknown

Registered

2014-10-24

Start date

2013-12-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small lung cancer

Interventions

experimental group:TKI combined chemotherapy

control group:TKI alone

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1 The patients with non small cell lung cancer;2 The patients from 18 years to 80 years old;3 The patients with EGFR mutation positive;4 The adenocarcinoma patiens with EGFR unknown mutation, non-small cell lung cancer patients with no smoking history;5 The non-small cell lung cancer patients in IIIB-IV of TNM staging; 6 The non-small cell lung cancer patients in ? - ?A of TNM staging can not be operated for some reason;7 The non-small cell lung cancer patients with 0-1 in PS scores.

Exclusion criteria

Exclusion criteria: 1. The patients with serious heart, liver, kidney disease; 2. The non-small cell lung cancer patients received operation treatment or chemotherapy; 3. The non-small cell lung cancer patients cannot tolerate chemotherapy; 4. The patients with negative EGFR mutation.

Design outcomes

Primary

Measure	Time frame
PF;	—

Secondary

Measure	Time frame
OS;efficac;	—

Contacts

Public ContactLi Yu

qlhxk@163.com+86 13791122770

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026